echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hisun Pharmaceutical: Bicalutamide tablets passed the consistency evaluation of generic drugs

    Hisun Pharmaceutical: Bicalutamide tablets passed the consistency evaluation of generic drugs

    • Last Update: 2021-04-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 9th, Hisun Pharmaceutical announced that it received the "Drug Supplementary Application Approval Notice" for bicalutamide tablets approved and issued by the National Medical Products Administration.


    Bicalutamide tablets are mainly suitable for the treatment of advanced prostate cancer.


    According to statistics, the global sales of bicalutamide tablets in 2020 will be approximately US$394,949,200, of which China’s sales are approximately US$112,448,100 (data from the IMS database).


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.